Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates

分组1 - Collegium Pharmaceutical reported quarterly earnings of $1.68 per share, exceeding the Zacks Consensus Estimate of $1.62 per share, and showing an earnings surprise of +3.70% [1] - The company achieved revenues of $188 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.23%, compared to $145.28 million in the same quarter last year [2] - Over the last four quarters, Collegium Pharmaceutical has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] 分组2 - The stock has added approximately 3.8% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is $1.80 on revenues of $188.37 million, and for the current fiscal year, it is $6.90 on revenues of $747.55 million [7] - The Zacks Industry Rank for Medical - Drugs is currently in the top 35% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]